journal article·2020-09

Formation of nanosized Gd(III) coordination networks with tripodal amine-N-oxide type ligand through microemulsions to achieve high relaxivity and exceptional stability for MRI applications

Na Xu, Kehan Xu, Weijun Tang, Yun Ding, Aiguo Hu

Journal of Materials Science· Volume 55· Issue 27
Publisher page

Abstract

Gadolinium(III) complexes, such as Gd-DTPA (Magnevist®) and Gd-DOTA (Dotarem®), are widely used as magnetic resonance imaging (MRI) contrast agents (CAs) in clinical practice. Both high relaxivity and stability are crucial requirements for Gd(III)-based materials to be used as MRI-CAs. The relaxivity is generally improved by increasing the hydration number (q) and/or embedding Gd(III) complexes in/onto slow rotating objects, while the coordination stability can be enhanced when nitrogen donors are replaced with oxygen donors according to the hard-soft-acid-base (HSAB) principle. In this work, we synthesized a tripodal hexadentate all-oxygen-donor ligand bearing three pairs of carboxylate and amine-N-oxide chelating groups and used microemulsion technique to further form nanosized coordination networks. The obtained Gd(III)-containing nanoparticles exhibited a narrow size distribution centered at 90 nm according to dynamic laser scattering and transmission electron microscopy analysis. The relaxivity of the nanoparticles reached 25.95 s−1 per mM of Gd(III), about six times higher than that of the commercial MRI-CAs. The competing coordination experiments showed that Gd(III) ions were firmly bonded in the coordination networks, complying well with the safety requirement for clinical applications. Moreover, the nanoparticles had low cytotoxicity and displayed good biocompatibility for potential in vivo applications.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Lanthanide and Transition Metal Complexes · Metal-Organic Frameworks: Synthesis and Applications · Magnetism in coordination complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. Wallyn J, Anton N, Akram S, Vandamme TF (2019) Biomedical imaging: principles, technologies, clinical aspects, contrast agents, limitations and future trends in nanomedicines pharm. Res 36:78. https://doi.org/10.1007/s11095-019-2608-510.1007/s11095-019-2608-5 ↗
2. Akakuru OU, Iqbal MZ, Saeed M et al (2019) The transition from metal-based to metal-free contrast agents for T1 magnetic resonance imaging enhancement. Bioconjugate Chem 30:2264–2286. https://doi.org/10.1021/acs.bioconjchem.9b0049910.1021/acs.bioconjchem.9b00499 ↗
3. Bottrill M, Kwok L, Long N (2006) Lanthanoids in magnetic resonance imaging. Chem Soc Rev 35:557–571. https://doi.org/10.1039/b516376p10.1039/b516376p ↗
4. Datta A, Raymond KN (2009) Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res 42:938–94710.1021/ar800250h ↗
5. Raymond KN, Pierre VC (2005) Next generation, high relaxivity gadolinium MRI agents. Bioconjugate Chem 16:3–8. https://doi.org/10.1021/bc049817y10.1021/bc049817y ↗
6. Wahsner J, Gale EM, Rodriguez-Rodriguez A, Caravan P (2019) Chemistry of MRI contrast agents: current challenges and new frontiers. Chem Rev 119:957–1057. https://doi.org/10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
7. Villaraza AJL, Bumb A, Brechbiel MW (2010) Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 110:2921–2959. https://doi.org/10.1021/Cr900232t10.1021/Cr900232t ↗
8. Zhang B, Cheng L, Duan B et al (2019) Gadolinium complexes of diethylenetriamine-N-oxide pentaacetic acid-bisamide: a new class of highly stable MRI contrast agents with a hydration number of 3. Dalton Trans 48:1693–1699. https://doi.org/10.1039/C8DT04478C10.1039/C8DT04478C ↗
9. Hermann P, Kotek J, Kubicek V, Lukes I (2008) Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans. https://doi.org/10.1039/b719704g10.1039/b719704g ↗
10. Aime S, Calabi L, Cavallotti C et al (2004) [Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents. Inorg Chem 43:7588–7590. https://doi.org/10.1021/ic048969210.1021/ic0489692 ↗
11. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293–2352. https://doi.org/10.1021/cr980440x10.1021/cr980440x ↗
12. Chan K, Wong W-T (2007) Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. Coord Chem Rev 251:2428–2451. https://doi.org/10.1016/j.ccr.2007.04.01810.1016/j.ccr.2007.04.018 ↗
13. Caravan P (2006) Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35:512–52310.1039/b510982p ↗
14. Chen Y, Zhu Q, Cui X et al (2014) Preparation of highly efficient MRI contrast agents through complexation of cationic GdIII-containing metallosurfactant with biocompatible polyelectrolytes. Chem Eur J 20:12477–12482. https://doi.org/10.1002/chem.20140253010.1002/chem.201402530 ↗
15. Martinelli J, Thangavel K, Tei L, Botta M (2014) Dendrimeric beta-cyclodextrin/Gd(III) chelate supramolecular host-guest adducts as high-relaxivity MRI probes. Chem Eur J 20:10944–10952. https://doi.org/10.1002/chem.20140241810.1002/chem.201402418 ↗
16. Xiong R, Cheng L, Tian Y et al (2016) Hyperbranched polyethylenimine based polyamine-N-oxide-carboxylate chelates of gadolinium for high relaxivity MRI contrast agents. RSC Adv 6:28063–2806810.1039/C6RA03589B ↗
17. Menjoge AR, Kannan RM, Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 15:171–18510.1016/j.drudis.2010.01.009 ↗
18. Fedorenko S, Bespalova S, Mustafina A et al (2016) Tuning the non-covalent confinement of Gd(III) complexes in silica nanoparticles for high T1-weighted MR imaging capability. Colloids Surf B. https://doi.org/10.1016/j.colsurfb.2016.10.02510.1016/j.colsurfb.2016.10.025 ↗
19. W Lin, W Rieter, K Taylor-Pashow (2009) Modular synthesis of functional nanoscale coordination polymers. Angewandte Chemie (International ed. in English) 48: 650–658. https://doi.org/10.1002/anie.20080338710.1002/anie.200803387 ↗
20. Catala L, Volatron F, Brinzei D, Mallah T (2009) Functional coordination nanoparticles. Inorg Chem 48:3360–3370. https://doi.org/10.1021/ic801257410.1021/ic8012574 ↗
21. Spokoyny AM, Kim D, Sumrein A, Mirkin CA (2009) Infinite coordination polymer nano- and microparticle structures. Chem Soc Rev 38:1218–1227. https://doi.org/10.1039/b807085g10.1039/b807085g ↗
22. Rocca J, Liu D, Lin W (2011) Nanoscale metal-organic frameworks for biomedical imaging and drug delivery. Acc Chem Res 44:957–968. https://doi.org/10.1021/ar200028a10.1021/ar200028a ↗
23. He C, Liu D, Lin W (2015) Nanomedicine applications of hybrid nanomaterials built from metal-ligand coordination bonds: nanoscale metal-organic frameworks and nanoscale coordination. Polymers Chem Rev 115:11079–11108. https://doi.org/10.1021/acs.chemrev.5b0012510.1021/acs.chemrev.5b00125 ↗
24. Rowe M, Chang C-C, Thamm D et al (2009) Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir 25:9487–9499. https://doi.org/10.1021/la900730b10.1021/la900730b ↗
25. Rowe M, Thamm D, Kraft S, Boyes S (2009) Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromol 10:983–993. https://doi.org/10.1021/bm900043e10.1021/bm900043e ↗
26. Rieter WJ, Taylor KML, An HY, Lin WL, Lin WB (2006) Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J Am Chem Soc 128:9024–9025. https://doi.org/10.1021/Ja062744410.1021/Ja0627444 ↗
27. Dong X, Ding YX, Wu P, Wang CC, Schafer CG (2017) Preparation of MRI-visible gadolinium methacrylate nanoparticles with low cytotoxicity and high magnetic relaxivity. J Mater Sci 52:7625–7636. https://doi.org/10.1007/s10853-017-1070-110.1007/s10853-017-1070-1 ↗
28. Barker-Griffith A, Goldberg J, Abraham J (2011) Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol 129:661–663. https://doi.org/10.1001/archophthalmol.2011.8910.1001/archophthalmol.2011.89 ↗
29. Cowper S, Kuo P, Bucala R (2007) Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. Arthritis Rheum 56:3173–3175. https://doi.org/10.1002/art.2292610.1002/art.22926 ↗
30. Cowper S (2008) Gadolinium—is it to blame? J Cutan Pathol 35:520–522. https://doi.org/10.1111/j.1600-0560.2008.01027.x10.1111/j.1600-0560.2008.01027.x ↗
31. Wollanka H, Weidenmaier W, Giersig C (2009) NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 24:3882–3884. https://doi.org/10.1093/ndt/gfp49410.1093/ndt/gfp494 ↗
32. Ayers PW, Parr RG, Pearson RG (2006) Elucidating the hard/soft acid/base principle: a perspective based on half-reactions. J Chem Phys 124:194107. https://doi.org/10.1063/1.219688210.1063/1.2196882 ↗
33. Pearson RG (1963) Hard and soft acids and bases. J Am Chem Soc 85:3533–3539. https://doi.org/10.1021/ja00905a00110.1021/ja00905a001 ↗
34. Liu X, Lin L, Feng X (2011) Chiral N,N′-Dioxides: new ligands and organocatalysts for catalytic asymmetric reactions. Acc Chem Res 44:574–587. https://doi.org/10.1021/ar200015s10.1021/ar200015s ↗
35. Gao B, Wen Y, Yang Z, Huang X, Liu X, Feng X (2008) Asymmetric ring opening of meso-epoxides with aromatic amines catalyzed by a new proline-based N,N′-dioxide-indium Tris(triflate) complex. Adv Synth Catal 350:385–390. https://doi.org/10.1002/adsc.20070047410.1002/adsc.200700474 ↗
36. Liu X, Lin L, Feng X (2009) Amide-based bifunctional organocatalysts in asymmetric reactions. Chem Commun. https://doi.org/10.1039/B913411E10.1039/B913411E ↗
37. Shang D, Liu Y, Zhou X, Liu X, Feng X (2009) A N, N′-dioxide–copper(II) complex as an efficient catalyst for the enantioselective and diastereoselective mannich-type reaction of Glycine Schiff bases with aldimines. Chem Eur J 15:3678–3681. https://doi.org/10.1002/chem.20090011810.1002/chem.200900118 ↗
38. Martins AF, Eliseeva SV, Carvalho HF et al (2014) A bis(pyridine N-oxide) analogue of DOTA: relaxometric properties of the Gd(III) complex and efficient sensitization of visible and NIR-emitting lanthanide(III) cations including Pr(III) and Ho(III). Chem Eur J 20:14834–14845. https://doi.org/10.1002/chem.20140385610.1002/chem.201403856 ↗
39. Zadmard R, Schrader T, Grawe T, Kraft A (2002) Self-assembly of molecular capsules in polar solvents. Org Lett 4:1687–1690. https://doi.org/10.1021/ol025763110.1021/ol0257631 ↗
40. Mastalerz M, Lauer J, Zhang W-S, Rominger F, Schröder R (2017) Shape-persistent [4+4] imine cages with a truncated tetrahedral geometry. Chem Eur J. https://doi.org/10.1002/chem.20170571310.1002/chem.201705713 ↗
41. Bellin M-F, van der Molen A (2008) Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 66:160–167. https://doi.org/10.1016/j.ejrad.2008.01.02310.1016/j.ejrad.2008.01.023 ↗
42. Laurent S, Elst LV, Muller RN (2006) Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1:128–13710.1002/cmmi.100 ↗
43. Nimesh S, Kumar R, Chandra R (2006) Novel polyallylamine–dextran sulfate–DNA nanoplexes: highly efficient non-viral vector for gene delivery. Int J Pharm 320:143–149. https://doi.org/10.1016/j.ijpharm.2006.03.05010.1016/j.ijpharm.2006.03.050 ↗
44. Goodman CM, McCusker CD, Yilmaz T, Rotello VM (2004) Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem 15:897–900. https://doi.org/10.1021/bc049951i10.1021/bc049951i ↗
45. Choimet M, Hyoung-Mi K, Jae-Min O, Tourrette A, Drouet C (2016) Nanomedicine: interaction of biomimetic apatite colloidal nanoparticles with human blood components. Colloids Surf B 145:87–94. https://doi.org/10.1016/j.colsurfb.2016.04.03810.1016/j.colsurfb.2016.04.038 ↗
46. Han Y, Wang X, Dai H, Li S (2012) Nanosize and surface charge effects of hydroxyapatite nanoparticles on red blood cell suspensions. ACS Appl Mater Interfaces 4:4616–4622. https://doi.org/10.1021/am300992x10.1021/am300992x ↗
47. Boas U, Heegaard PMH (2004) Dendrimers in drug research. Chem Soc Rev 33:43–63. https://doi.org/10.1039/B309043B10.1039/B309043B ↗
48. Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Fröhlich E (2009) The role of nanoparticle size in hemocompatibility. Toxicology 258:139–147. https://doi.org/10.1016/j.tox.2009.01.01510.1016/j.tox.2009.01.015 ↗
49. Loretz B, Bernkop-Schnürch A (2007) vitro cytotoxicity testing of non-thiolated and thiolated chitosan nanoparticles for oral gene delivery. Nanotoxicology 1:139–148. https://doi.org/10.1080/1743539070155420010.1080/17435390701554200 ↗
50. Wang Q, Shen M, Zhao T et al (2015) Low toxicity and long circulation time of polyampholyte-coated magnetic nanoparticles for blood pool contrast agents. Sci Rep 5:7774. https://doi.org/10.1038/srep0777410.1038/srep07774 ↗
51. Zhu Q, Yang H, Li YY et al (2016) HP-DO3A-based amphiphilic MRI contrast agents and relaxation enhancement through their assembly with polyelectrolytes. J Mater Chem B 4:7241–724810.1039/C6TB01998F ↗
52. Zhu Q, Yuan ZY, Qian WQ et al (2017) Spherical polyelectrolyte brushes as a novel platform for paramagnetic relaxation enhancement and passive Tumor Targeting. Adv Healthcare Mater 6:201700071. https://doi.org/10.1002/Adhm.20170007110.1002/Adhm.201700071 ↗
53. McKinlay AC, Morris RE, Horcajada P et al (2010) BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl 49:6260–6266. https://doi.org/10.1002/anie.20100004810.1002/anie.201000048 ↗
54. Park KM, Kim H, Murray J, Koo J, Kim K (2017) A facile preparation method for nanosized MOFs as a multifunctional material for cellular imaging and drug delivery. Supramol Chem 29:441–445. https://doi.org/10.1080/10610278.2016.126635910.1080/10610278.2016.1266359 ↗
55. Verwilst P, Eliseeva SV, Vander Elst L et al (2012) A tripodal ruthenium-gadolinium metallostar as a potential α(v)β(3) integrin specific bimodal imaging contrast agent. Inorg Chem 51:6405–6411. https://doi.org/10.1021/ic300717m10.1021/ic300717m ↗
56. Liu D, He C, Poon C, Lin W (2014) Theranostic nanoscale coordination polymers for magnetic resonance imaging and bisphosphonate delivery. J Mater Chem B 2:8249–8255. https://doi.org/10.1039/C4TB00751D10.1039/C4TB00751D ↗
57. Park J, Baek M, Choi E et al (2009) Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T 1 MRI contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T 1 MR images. ACS Nano 3:3663–3669. https://doi.org/10.1021/nn900761s10.1021/nn900761s ↗
58. Bridot J-L, Faure A-C, Laurent S et al (2007) Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 129:5076–5084. https://doi.org/10.1021/ja068356j10.1021/ja068356j ↗